This site is intended for healthcare professionals only.
This site is intended for healthcare professionals only.
Want more information?
contact reimbursement@pacira.com or call the EXPAREL reimbursement hotline: 855-793-9727
46% reduction in pain vs placebo (P<0.0001)2*†
78% reduction in opioid use vs placebo (P<0.0001)3*†
No cumbersome pumps or catheters necessary
*Results from a phase 3, double-blind, randomized, controlled trial that compared the postsurgical analgesia efficacy, safety, and pharmacokinetics of EXPAREL 133 mg (10 mL) and placebo in a total shoulder arthroplasty or rotator cuff repair. Primary and secondary end points: pain intensity through 48 hours postsurgery, as measured by area under the curve of visual analog scale pain intensity scores, and total postsurgical opioid consumption.2 Rescue opioids for pain were available upon patient request.
†The clinical benefit of the decrease in opioid consumption was not demonstrated in pivotal trials.
Results from an EXPAREL phase 4, double-blind, randomized, controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in a total knee arthroplasty study. Primary end points: area under the curve of visual analog scale pain intensity scores 12 to 48 hours postsurgery; total opioid consumption 0 to 48 hours postsurgery. Rescue opioids for pain were available upon patient request.
*The clinical benefit of the decrease in opioid consumption was not demonstrated in pivotal trials.
How to Use EXPAREL: Videos and Case Reports by Procedure
